These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 9703462)

  • 1. 2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N - methylamide (SDZ NKT 343), a potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models.
    Walpole C; Ko SY; Brown M; Beattie D; Campbell E; Dickenson F; Ewan S; Hughes GA; Lemaire M; Lerpiniere J; Patel S; Urban L
    J Med Chem; 1998 Aug; 41(17):3159-73. PubMed ID: 9703462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist.
    Walpole CS; Brown MC; James IF; Campbell EA; McIntyre P; Docherty R; Ko S; Hedley L; Ewan S; Buchheit KH; Urban LA
    Br J Pharmacol; 1998 May; 124(1):83-92. PubMed ID: 9630347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.
    Emonds-Alt X; Proietto V; Steinberg R; Oury-Donat F; Vigé X; Vilain P; Naline E; Daoui S; Advenier C; Le Fur G; Maffrand JP; Soubrié P; Pascal M
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1171-9. PubMed ID: 12438541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of the central tachykinin NK1 receptor during maintenance of mechanical hypersensitivity induced by diabetes in the rat.
    Field MJ; McCleary S; Boden P; Suman-Chauhan N; Hughes J; Singh L
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1226-32. PubMed ID: 9618426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist.
    Cialdai C; Tramontana M; Patacchini R; Lecci A; Catalani C; Catalioto RM; Meini S; Valenti C; Altamura M; Giuliani S; Maggi CA
    Eur J Pharmacol; 2006 Nov; 549(1-3):140-8. PubMed ID: 16979621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
    Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
    J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling.
    Frølund B; Jensen LS; Guandalini L; Canillo C; Vestergaard HT; Kristiansen U; Nielsen B; Stensbøl TB; Madsen C; Krogsgaard-Larsen P; Liljefors T
    J Med Chem; 2005 Jan; 48(2):427-39. PubMed ID: 15658856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor antagonist.
    Di Fabio R; Griffante C; Alvaro G; Pentassuglia G; Pizzi DA; Donati D; Rossi T; Guercio G; Mattioli M; Cimarosti Z; Marchioro C; Provera S; Zonzini L; Montanari D; Melotto S; Gerrard PA; Trist DG; Ratti E; Corsi M
    J Med Chem; 2009 May; 52(10):3238-47. PubMed ID: 19388677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axially chiral N-benzyl-N,7-dimethyl-5-phenyl-1, 7-naphthyridine-6-carboxamide derivatives as tachykinin NK1 receptor antagonists: determination of the absolute stereochemical requirements.
    Ikeura Y; Ishichi Y; Tanaka T; Fujishima A; Murabayashi M; Kawada M; Ishimaru T; Kamo I; Doi T; Natsugari H
    J Med Chem; 1998 Oct; 41(22):4232-9. PubMed ID: 9784098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of selective NK(1) receptor antagonist CI-1021 in animal models of inflammatory and neuropathic pain.
    Gonzalez MI; Field MJ; Hughes J; Singh L
    J Pharmacol Exp Ther; 2000 Aug; 294(2):444-50. PubMed ID: 10900217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent and selective non-benzodioxole-containing endothelin-A receptor antagonists.
    Tasker AS; Sorensen BK; Jae HS; Winn M; von Geldern TW; Dixon DB; Chiou WJ; Dayton BD; Calzadila S; Hernandez L; Marsh KC; WuWong JR; Opgenorth TJ
    J Med Chem; 1997 Jan; 40(3):322-30. PubMed ID: 9022798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists.
    Hipskind PA; Howbert JJ; Bruns RF; Cho SS; Crowell TA; Foreman MM; Gehlert DR; Iyengar S; Johnson KW; Krushinski JH; Li DL; Lobb KL; Mason NR; Muehl BS; Nixon JA; Phebus LA; Regoli D; Simmons RM; Threlkeld PG; Waters DC; Gitter BD
    J Med Chem; 1996 Feb; 39(3):736-48. PubMed ID: 8576917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958.
    Hawkinson JE; Szoke BG; Garofalo AW; Hom DS; Zhang H; Dreyer M; Fukuda JY; Chen L; Samant B; Simmonds S; Zeitz KP; Wadsworth A; Liao A; Chavez RA; Zmolek W; Ruslim L; Bova MP; Holcomb R; Butelman ER; Ko MC; Malmberg AB
    J Pharmacol Exp Ther; 2007 Aug; 322(2):619-30. PubMed ID: 17470643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
    Dziadulewicz EK; Bevan SJ; Brain CT; Coote PR; Culshaw AJ; Davis AJ; Edwards LJ; Fisher AJ; Fox AJ; Gentry C; Groarke A; Hart TW; Huber W; James IF; Kesingland A; La Vecchia L; Loong Y; Lyothier I; McNair K; O'Farrell C; Peacock M; Portmann R; Schopfer U; Yaqoob M; Zadrobilek J
    J Med Chem; 2007 Aug; 50(16):3851-6. PubMed ID: 17630726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural analysis and optimization of NK(1) receptor antagonists through modulation of atropisomer interconversion properties.
    Albert JS; Ohnmacht C; Bernstein PR; Rumsey WL; Aharony D; Alelyunas Y; Russell DJ; Potts W; Sherwood SA; Shen L; Dedinas RF; Palmer WE; Russell K
    J Med Chem; 2004 Jan; 47(3):519-29. PubMed ID: 14736234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of structure-activity relationships with the N-(3-acyloxy-2-benzylpropyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea template for vanilloid receptor 1 antagonism.
    Lee J; Kim SY; Lee J; Kang M; Kil MJ; Choi HK; Jin MK; Wang Y; Toth A; Pearce LV; Lundberg DJ; Tran R; Blumberg PM
    Bioorg Med Chem; 2004 Jul; 12(13):3411-20. PubMed ID: 15186827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of the potent peptide FK888 with unusual aminoacids: effects on activity on neurokinin receptors.
    Caliendo G; Greco G; Grieco P; Perissutti E; Santagada V; Calignano A; Mancuso F; Novellino E
    Farmaco; 1996 Mar; 51(3):197-201. PubMed ID: 8688142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proline bis-amides as potent dual orexin receptor antagonists.
    Bergman JM; Roecker AJ; Mercer SP; Bednar RA; Reiss DR; Ransom RW; Meacham Harrell C; Pettibone DJ; Lemaire W; Murphy KL; Li C; Prueksaritanont T; Winrow CJ; Renger JJ; Koblan KS; Hartman GD; Coleman PJ
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1425-30. PubMed ID: 18207395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets.
    Duffy RA; Morgan C; Naylor R; Higgins GA; Varty GB; Lachowicz JE; Parker EM
    Pharmacol Biochem Behav; 2012 Jul; 102(1):95-100. PubMed ID: 22497992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.